Published in Cancer on December 13, 2010
Analysis of second-harmonic-generation microscopy in a mouse model of ovarian carcinoma. J Biomed Opt (2012) 0.94
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila) (2012) 0.86
A branching process model of ovarian cancer. J Theor Biol (2012) 0.83
Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers. Math Biosci (2012) 0.81
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary. J Cancer Res Clin Oncol (2012) 0.77
Mathematical models of breast and ovarian cancers. Wiley Interdiscip Rev Syst Biol Med (2016) 0.75
Reducing ovarian cancer death rates through screening. Cancer (2010) 0.75
Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials. Diagnostics (Basel) (2017) 0.75
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med (2007) 7.31
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Non-evidence-based ICD implantations in the United States. JAMA (2011) 5.05
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Effect of clinical decision-support systems: a systematic review. Ann Intern Med (2012) 3.42
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol (2005) 3.31
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol (2009) 3.08
Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08
Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril (2004) 3.03
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
An economic evaluation of prolonged mechanical ventilation. Crit Care Med (2007) 2.93
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med (2003) 2.72
The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72
Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril (2004) 2.59
Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol (2005) 2.50
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49
Acute myocardial infarction in pregnancy: a United States population-based study. Circulation (2006) 2.49
Evaluating human papillomavirus vaccination programs. Emerg Infect Dis (2004) 2.47
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. Am J Obstet Gynecol (2011) 2.36
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res (2011) 2.32
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol (2012) 2.21
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev (2013) 2.18
Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol (2013) 2.17
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Dissemination of Evidence-based Practice Center reports. Ann Intern Med (2005) 2.05
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol (2010) 1.94
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 1.90
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 1.90
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 1.89
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila) (2009) 1.78
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell (2003) 1.76
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol (2006) 1.75
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res (2006) 1.74
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol (2005) 1.71
Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med (2005) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Enabling health care decisionmaking through clinical decision support and knowledge management. Evid Rep Technol Assess (Full Rep) (2012) 1.68
Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med (2014) 1.67
Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med (2008) 1.67
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol (2008) 1.65
Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2015) 1.63
Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med (2011) 1.62
Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med (2003) 1.61
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator. Health Aff (Millwood) (2005) 1.60
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur J Endocrinol (2008) 1.59
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. Gynecol Oncol (2012) 1.58
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril (2006) 1.56
Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol (2013) 1.56
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer (2003) 1.56
Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol (2003) 1.55
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res (2003) 1.54
FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol (2005) 1.52
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Hum Mol Genet (2013) 1.52
Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. Cardiol J (2011) 1.50
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2003) 1.49
Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol (2008) 1.49